Longer Duration of Treatment with ICIs Associated with a Higher Rate of Complete Response Among Patients with MMRd Cancers By Ogkologos - March 5, 2025 532 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a systematic review of published studies Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Stress-Induced Immune Changes May Help Cancer Spread April 2, 2024 ESMO Calls on EU Research Ministers to Prioritise Cancer Research Funding... September 25, 2025 Maximizing the Prospects for Progress Against Cancer June 11, 2018 Medical Cannabis Formulation May Be Capable of Killing Breast Cancer Cells,... May 21, 2021 Load more HOT NEWS Concurrent Intrathecal and Intravenous Nivolumab is Safe and Feasible with Preliminary... 9/11 Firefighter Dies Of Cancer From Working At Ground Zero Severe mental illness linked to low attendance at cancer screening A “Living Medicine:” Engineered E. coli Shrink Tumors in Mice
